Serum Copeptin as the Predictor for Acute Heart Failure Complication of Acute Myocardial Infarction in Patients with ST-Segment Elevation

Ardi Putranto Ari Supomo, JB. Suparyatmo, Dian Ariningrum


Acute Myocardial Infarction (AMI) is necrotic cardiac muscle cells due to unstable ischemic syndrome. Therapy monitoring is needed because various complications may occur (Heart Failure/HF). ST-Segment Elevation Myocardial Infarction (STEMI) can develop to Acute Heart Failure (AHF) due to myocardial dysfunction, transmural heart disease, pathological cardiac remodeling. Copeptin is an antidiuretic hormone which increases in the cardiac event. It can be used as a predictor of a further cardiac event. This study aimed to determine the role of serum copeptin level as a predictor of AHF complication in STEMI patients. A prospective cohort study was performed in 85 adult STEMI patients admitted to The Clinical Pathology Installation of Dr. Moewardi Hospital, Surakarta. Data with normal and abnormal distribution were presented in mean±Standard Deviation (SD) and median (min-max), respectively. Statistical analysis was performed using Kolmogorov-Smirnov, bivariate, and multivariate analysis for RR with Confidence Interval (CI) of 95% and p < 0.05 was considered significant. The copeptin cut-off point was determined using the ROC curve. Bivariate and multivariate analysis showed a higher copeptin level in STEMI patients with AHF compared to that of non-AHF (RR=5.172, CI 95% 1.795-14.902, p=0.002 and RR=1.889, CI 95% 1.156-3.086, p=0.001; respectively). The STEMI patients with an elevated level of copeptin showed an increased risk of AHF (STEMI with elevated copeptin level vs STEMI with normal copeptin level; 28.74% vs. 88.91%). Copeptin level is significantly related to AHF complication in STEMI patient, the higher level of copeptin led to the higher the risk of AHF.


ST-segment elevation myocardial infarction, copeptin, acute heart failure

Full Text:



Anderson J. L., Morrow D. A. 2017. Acute myocardial infarction. NEJM. 376: 2053 – 2064.

Perhimpunan dokter spesialis kardiovaskular Indonesia. 2018. Pedoman tata laksana sindrom koroner akut. Edisi IV. 1 – 94.

Badan penelitian dan pengembangan kesehatan Kementerian kesehatan Republik Indonesia. 2013. Riset kesehatan dasar 2013. Edisi I. 1 – 306.

Hastuti Y. E., Elfi E. F., Pertiwi D. 2013. Hubungan kadar troponin T dengan lama perawatan pasien infark miokard akut di RSUP Dr. M. Djamil Padang periode 01 Januari – 31 Desember 2013. Jurnal kesehatan Andalas. 6(2): 423 – 428.

Badan penelitian dan pengembangan kesehatan Kementerian kesehatan Republik Indonesia. 2007. Riset kesehatan dasar, Laporan Nasional 2007. Edisi I. 1 – 306.

Perhimpunan dokter spesialis kardiovaskular Indonesia. 2015. Pedoman tata laksana gagal jantung. Edisi I. 1 – 56.

Balling L., Gustafsson F. 2016. Copeptin in heart failure. Advances in clinical chemistry. 73: 29 – 64.

Voors A. A., Haehling S. V., Anker S. D., et al. 2009. C-terminal provasopressin (copeptin) is strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. European Heart journal. 30: 1187 – 1194.

Schurtz G., Lamblin N., Bauters C., Goldstein P., Lemesle G. 2015. Copeptin in acute coronary syndrome and heart failure management: state of the art and future directions. Journal archives of cardiovascular disease. 108: 398 – 407.

Elshafei A., Abdalla G., El-Motaal O. A., Salman T. 2013. Copeptin: a neuroendocrine biomarker in acute myocardial infarction. Annual review & research in biology. SCIENCEDOMAIN International. 3(4): 1040 – 1054.

Nursalim A., Suryaatmadja M., Panggabean M. 2013. Potential clinical application of novel cardiac biomarkers for acute myocardial infarction. Acta medical Indonesiana – The Indonesian journal of internal medicine. 45(3): 240 – 250.

Kristyagita A., Siswanto B. B. 2015. The role of copeptin as a novel cardiovascular biomarker. Medical journal Indonesia. 24: 59 – 66.

Ay M. O., Erenler A. K., Dogan T., Yetim M. 2017. Diagnostic value of copeptin in acute myocardial infarction. European review for Medical and pharmacological sciences. 21: 1576 – 1582.

Chung S. R., Yang T. H., Shin H. C., et al. 2016. Initial total bilirubin and clinical outcome in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with drug-eluting stents. Circulation Journal. 90: 1437 – 1445.

Cahill T. J., Kharbanda R. K. 2017. Heart failure after myocardial infarctiom in the era of primary percutaneus coronary intervention: Mechanisms, incidence and identification of patients at risk. World journal of cardiology. 9(5): 407 – 415.

Gho J. M. I. H., Postema P. G., Conjin M., et al. 2016. Heart failure following STEMI: a contemporary cohort study of incidence and prognostic factors. Open Heart Journal. 1 – 8.

Núňez J., Sanchis J., Núňez E. 2010. Effect of acute heart failure following discharge in patients with non-st elevation acute coronary syndrome on the subsequent risk of death or acute myocardial infarction. Rev Esp Cardiol. 63(9): 1035 – 1044.

Perhimpunan dokter spesialis endokrinologi Indonesia. 2015. Konsensus Pengelolaan dan Pencegahan Diabetes Melitus tipe 2 di Indonesia. Edisi I. 1 – 93.

Carillo S., Zhang Y., Fay R., et al., 2014. Heart failure with systolic dysfunction complicating acute myocardial infarction — differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial. Archives of Cardiovascular Disease. 107: 149 – 157.

Ali W. M., Zubaid M., El-Menyar A., et al. 2010. The prevalence and outcome of hypertension in patients with acute coronary syndrome in six Middle-Eastern countries. Blood Press Journal. 20 : 20 – 26.

Feistritzer H. J., Klug G., Reinstadler S. J., et al. 2016. Novel biomarkers predicting cardiac function after acute myocardial infarction. British Medical Bulletin. 119: 63 – 74.

Ma Q. Q., Fan X. D., Hao Y. Y., Ma F. 2018. Short- and long-term prognostic value of hyponatremia in patients with acute coronary syndrome: a systematic review and meta analysis. PLOS ONE Journal. 13(3): 1 – 16.

O’Malley R. G., Bonaca M. P., Scirica B. M., et al. 2014. Prognostic performance of multiple biomarkers in patients with non-st elevation acute coronary syndrome: analysis from MERLIN-TIMI 36. Journal of the American College of Cardiology. 1 – 19.

Harris R. J., et al. 1985. A primer of multivariate statistics. New York: Academic Press. 2: 129 – 257.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.